Guoming Shi

机构：Fudan University, Zhongshan Hospital

发表论文 13 篇 · 总被引 69 次 · h-index 5

代表论文

• Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study (2025 · The Lancet Oncology · 被引 20)
• Adjuvant lenvatinib after radical resection in patients with hepatocellular carcinoma (HCC): Preliminary analysis of a prospective, multi-center, single-arm study. (2022 · Journal of Clinical Oncology · 被引 13)
• Clinical outcomes from a phase I clinical trial of a novel oncolytic virus VG161 in patients with hepatocellular carcinoma (HCC) refractory after 2 prior lines of therapy including checkpoint inhibitors (CPI). (2024 · Journal of Clinical Oncology · 被引 10)
• Prognostic significance of nuclear RNA export factor 3 in hepatocellular carcinoma (2014 · Oncology Letters · 被引 8)
• Pemigatinib in Chinese patients with advanced/metastatic or surgically unresectable cholangiocarcinoma including FGFR2 fusion or rearrangement: Updated data from an open-label, single-arm, multicenter phase II study (CIBI375A201 study). (2022 · Journal of Clinical Oncology · 被引 6)
• Two stage, multi-center trial of cadonilimab and LM-302 for patients with CLDN18.2+ biliary tract cancer (BTC) that failed chemotherapy and PD-(L)1 antibody (ZSAB-Calm). (2024 · Journal of Clinical Oncology · 被引 3)